Indivior Pharmaceuticals (INDV) Enterprise Value (2021 - 2025)
Historic Enterprise Value for Indivior Pharmaceuticals (INDV) over the last 5 years, with Q3 2025 value amounting to -$445.0 million.
- Indivior Pharmaceuticals' Enterprise Value fell 2861.27% to -$445.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$445.0 million, marking a year-over-year decrease of 2861.27%. This contributed to the annual value of -$320.0 million for FY2024, which is 5622.44% up from last year.
- As of Q3 2025, Indivior Pharmaceuticals' Enterprise Value stood at -$445.0 million, which was down 2861.27% from -$510.0 million recorded in Q2 2025.
- Over the past 5 years, Indivior Pharmaceuticals' Enterprise Value peaked at -$320.0 million during Q4 2024, and registered a low of -$1.1 billion during Q4 2021.
- Over the past 5 years, Indivior Pharmaceuticals' median Enterprise Value value was -$689.0 million (recorded in 2023), while the average stood at -$659.1 million.
- As far as peak fluctuations go, Indivior Pharmaceuticals' Enterprise Value skyrocketed by 5622.44% in 2024, and later crashed by 3456.46% in 2025.
- Quarter analysis of 5 years shows Indivior Pharmaceuticals' Enterprise Value stood at -$1.1 billion in 2021, then grew by 18.97% to -$893.0 million in 2022, then rose by 18.14% to -$731.0 million in 2023, then soared by 56.22% to -$320.0 million in 2024, then crashed by 39.06% to -$445.0 million in 2025.
- Its last three reported values are -$445.0 million in Q3 2025, -$510.0 million for Q2 2025, and -$373.0 million during Q1 2025.